Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Aurinia Pharmaceuticals Inc’s stock clocked out at $15.53, down -0.96% from its previous closing price of $15.68. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 1.08 million shares were traded. AUPH stock price reached its highest trading level at $15.82 during the session, while it also had its lowest trading level at $15.41.
Ratios:
To gain a deeper understanding of AUPH’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.82 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.01. For the most recent quarter (mrq), Quick Ratio is recorded 5.17 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.17.
On November 07, 2025, Jefferies Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $21.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 05, 2025, while the target price for the stock was maintained at $15.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 01 ’25 when TANG KEVIN bought 1,000,000 shares for $10.12 per share. The transaction valued at 10,120,000 led to the insider holds 11,029,500 shares of the business.
TANG KEVIN bought 200,000 shares of AUPH for $2,336,000 on Aug 05 ’25. The Director now owns 11,329,500 shares after completing the transaction at $11.68 per share. On Aug 04 ’25, another insider, TANG KEVIN, who serves as the Director of the company, bought 100,000 shares for $11.34 each. As a result, the insider paid 1,134,000 and bolstered with 11,129,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 2047483904 and an Enterprise Value of 1786053504. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.68, and their Forward P/E ratio for the next fiscal year is 16.61. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.70 while its Price-to-Book (P/B) ratio in mrq is 5.60. Its current Enterprise Value per Revenue stands at 6.719 whereas that against EBITDA is 17.763.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.47, which has changed by 0.5509397 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $16.48, while it has fallen to a 52-week low of $6.55. The 50-Day Moving Average of the stock is 14.37%, while the 200-Day Moving Average is calculated to be 50.08%.
Shares Statistics:
It appears that AUPH traded 1.78M shares on average per day over the past three months and 1703330 shares per day over the past ten days. A total of 131.84M shares are outstanding, with a floating share count of 117.99M. Insiders hold about 10.51% of the company’s shares, while institutions hold 53.14% stake in the company. Shares short for AUPH as of 1763078400 were 8530321 with a Short Ratio of 4.79, compared to 1760486400 on 8394164. Therefore, it implies a Short% of Shares Outstanding of 8530321 and a Short% of Float of 7.090000000000001.
Earnings Estimates
The market rating for Aurinia Pharmaceuticals Inc (AUPH) is a result of the insights provided by 6.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.19, with high estimates of $0.22 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.84 and $0.74 for the fiscal current year, implying an average EPS of $0.78. EPS for the following year is $0.94, with 6.0 analysts recommending between $1.33 and $0.64.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $74.86M. It ranges from a high estimate of $76.61M to a low estimate of $73.26M. As of. The current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $59.87MFor the next quarter, 6 analysts are estimating revenue of $75.3M. There is a high estimate of $76.5M for the next quarter, whereas the lowest estimate is $74.4M.
A total of 6 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $282.55M, while the lowest revenue estimate was $279.2M, resulting in an average revenue estimate of $280.79M. In the same quarter a year ago, actual revenue was $235.13MBased on 6 analysts’ estimates, the company’s revenue will be $330.85M in the next fiscal year. The high estimate is $359.48M and the low estimate is $313.9M.
